Pharmasset Launches Pivotal Phase III of PSI-7977 in HCV
The next generation of hepatitis C virus (HCV) therapies moved a step closer to the corner drugstore with the initiation of Pharmasset Inc.'s pivotal Phase III studies of the HCV nucleotide analogue PSI-7977. The program will evaluate a 12-week, all-oral, interferon-free regimen of PSI-7977 and ribavirin in three groups of patients with HCV, independent of viral genotype or their ability to take interferon therapy.
The Princeton, N.J.-based company expects to submit data from the three Phase III trials in the second half of 2013, both in the U.S.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter